Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19342871 | 1.00 | UGT2B7 (0.37) | UGT2B7SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL19342872 | 1.00 | UGT2B7 (0.37) | UGT2B7SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL19342870 | 0.84 | KDM4E (0.34) | — | |
| SCHEMBL19328584 | 0.84 | KDM4E (0.34) | — | |
| SCHEMBL19342869 | 0.84 | KDM4E (0.34) | — | |
| SCHEMBL19328588 | 0.72 | TSHR (0.33) | TSHR | |
| SCHEMBL19354584 | 0.65 | HTR2A (0.45) | SLC6A4CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL19354510 | 0.65 | HTR2A (0.45) | SLC6A4CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL19435696 | 0.65 | UGT2B7 (0.52) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL30440392 | 0.65 | UGT2B7 (0.52) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765064-B1 | Alpha-hydroxy-beta-azido-tetrazoles | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-09-19 | — | — | US | claimed |
| US-20170260171-A1 | ALPHA-HYDROXY-BETA-AZIDO-TETRAZOLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-09-14 | — | — | US | claimed |
| US-9765064-B1 | Alpha-hydroxy-beta-azido-tetrazoles | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-09-19 | — | — | US | disclosed |
| US-20170260171-A1 | ALPHA-HYDROXY-BETA-AZIDO-TETRAZOLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260171-A1 | ALPHA-HYDROXY-BETA-AZIDO-TETRAZOLES | CYP8B1, HSD3B1, HSD17B1 | UGT2B7 44/4885SLC6A2 3947/4885SLC6A4 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.